For example, during the construction of ADPKD organoids, CRISPR/Cas9 technology facilitates the precise introduction of mutations in the PKD1 or PKD2 genes while also enabling the simulation of the “second hit” phenomenon at multiple time points. Here, PKD1 is linked to autosomal dominant polycystic kidney disease.